These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30779493)

  • 1. [TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE].
    Erdinest N; Solomon A
    Harefuah; 2019 Feb; 158(2):130-135. PubMed ID: 30779493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
    Paton DM
    Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
    Periman LM; Perez VL; Saban DR; Lin MC; Neri P
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease.
    Pflugfelder SC; Stern M; Zhang S; Shojaei A
    J Ocul Pharmacol Ther; 2017; 33(1):5-12. PubMed ID: 27906544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
    Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
    Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjunctival Tear Layer Temperature, Evaporation, Hyperosmolarity, Inflammation, Hyperemia, Tissue Damage, and Symptoms: A Review of an Amplifying Cascade.
    McMonnies CW
    Curr Eye Res; 2017 Dec; 42(12):1574-1584. PubMed ID: 29111837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cellular mechanisms of dry eye: from pathogenesis to treatment.
    Mantelli F; Massaro-Giordano M; Macchi I; Lambiase A; Bonini S
    J Cell Physiol; 2013 Dec; 228(12):2253-6. PubMed ID: 23696296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.
    Perez VL; Pflugfelder SC; Zhang S; Shojaei A; Haque R
    Ocul Surf; 2016 Apr; 14(2):207-15. PubMed ID: 26807723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for anti-inflammatory therapy in dry eye syndrome.
    de Paiva CS; Pflugfelder SC
    Arq Bras Oftalmol; 2008; 71(6 Suppl):89-95. PubMed ID: 19274418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
    Contreras-Ruiz L; Mir FA; Turpie B; Krauss AH; Masli S
    Exp Eye Res; 2016 Feb; 143():1-8. PubMed ID: 26463157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of silk fibroin in murine dry eye.
    Kim CE; Lee JH; Yeon YK; Park CH; Yang J
    Sci Rep; 2017 Mar; 7():44364. PubMed ID: 28281688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Quercetin in a Mouse Model of Experimental Dry Eye.
    Oh HN; Kim CE; Lee JH; Yang JW
    Cornea; 2015 Sep; 34(9):1130-6. PubMed ID: 26203745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
    Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME
    Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye.
    Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM
    J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.